Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosarelis Torres

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacology|December 3, 2014
Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairmentRosarelis Torres, William G Kramer, Paolo Baroldi
American Journal of Therapeutics|February 7, 2015
Absolute Bioavailability of TasimelteonRosarelis Torres, Marlene A Dressman, William G Kramer, et al.
Journal of Clinical Psychopharmacology|May 6, 2008
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studiesSteven G Potkin, Robert E Litman, Rosarelis Torres, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Journal of Sleep Research|June 21, 2021
Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteonRosarelis Torres, Michaela Fisher, Gunther Birznieks, et al.
The Pharmacogenomics Journal|March 14, 2026
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidoneSandra P Smieszek, Sean R Chadwick, Emily L Czeisler, et al.
The Journal of Clinical Psychiatry|January 18, 2024
Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled StudyRosarelis Torres, Emily L Czeisler, Sean R Chadwick, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacology|December 3, 2014
Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairmentRosarelis Torres, William G Kramer, Paolo Baroldi
American Journal of Therapeutics|February 7, 2015
Absolute Bioavailability of TasimelteonRosarelis Torres, Marlene A Dressman, William G Kramer, et al.
Journal of Clinical Psychopharmacology|May 6, 2008
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studiesSteven G Potkin, Robert E Litman, Rosarelis Torres, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Journal of Sleep Research|June 21, 2021
Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteonRosarelis Torres, Michaela Fisher, Gunther Birznieks, et al.
The Pharmacogenomics Journal|March 14, 2026
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidoneSandra P Smieszek, Sean R Chadwick, Emily L Czeisler, et al.
The Journal of Clinical Psychiatry|January 18, 2024
Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled StudyRosarelis Torres, Emily L Czeisler, Sean R Chadwick, et al.
Lancet (London, England)|October 16, 2015
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trialsSteven W Lockley, Marlene A Dressman, Louis Licamele, et al.
Pageof 1